STRO SUTRO BIOPHARMA, INC.
Research report · from SEC EDGAR · close 2026-07-16
$23.73 -8.7%
$393.2M mkt cap
executive summary
SUTRO BIOPHARMA, INC. (STRO) is a $393.2M company. Revenue is $102.5M (+65.2% y/y) at a -186% net margin. It is not yet profitable. Our health score is D (46/100). 3 red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$102.5M
+65.2% y/y
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-9.00).
⚠Active dilution shelf
An effective S-3 shelf with 2 prospectus filing(s) in 12 months — shares may be getting sold into the market.
⚠Weak fundamentals
Piotroski F-Score of 2/9 — most quality checks are failing.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$202.6M
Operating cash flow
-$177.2M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-16 by stocktools.ai.